296 related articles for article (PubMed ID: 30871495)
1. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
Mamidi TKK; Wu J; Hicks C
BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
Kumar Mamidi TK; Wu J; Hicks C
Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
[TBL] [Abstract][Full Text] [Related]
3. Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
Wu J; Mamidi TKK; Zhang L; Hicks C
Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30909550
[TBL] [Abstract][Full Text] [Related]
4. Interactions between Germline and Somatic Mutated Genes in Aggressive Prostate Cancer.
Mamidi TKK; Wu J; Hicks C
Prostate Cancer; 2019; 2019():4047680. PubMed ID: 31007957
[TBL] [Abstract][Full Text] [Related]
5. Mapping the Germline and Somatic Mutation Interaction Landscape in Indolent and Aggressive Prostate Cancers.
Mamidi TKK; Wu J; Hicks C
J Oncol; 2019; 2019():4168784. PubMed ID: 31814827
[TBL] [Abstract][Full Text] [Related]
6. Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer.
Wu J; Mamidi TKK; Zhang L; Hicks C
Int J Genomics; 2020; 2020():2641370. PubMed ID: 32724790
[TBL] [Abstract][Full Text] [Related]
7. Germline Mutations and Polymorphisms of Androgen Receptor in Prostate Cancer Patients: Frequency and Results of in Silico Analysis.
Sribudiani Y; Marwan DW; Aulanni’am A; Widodo MA; Purnomo BB; Panigoro R; Utomo AB
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2241-2245. PubMed ID: 30139231
[TBL] [Abstract][Full Text] [Related]
8. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor mutations and polymorphisms in African American prostate cancer.
Koochekpour S; Buckles E; Shourideh M; Hu S; Chandra D; Zabaleta J; Attwood K
Int J Biol Sci; 2014; 10(6):643-51. PubMed ID: 24948877
[TBL] [Abstract][Full Text] [Related]
10. Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility.
Solé X; Hernández P; de Heredia ML; Armengol L; Rodríguez-Santiago B; Gómez L; Maxwell CA; Aguiló F; Condom E; Abril J; Pérez-Jurado L; Estivill X; Nunes V; Capellá G; Gruber SB; Moreno V; Pujana MA
BMC Genomics; 2008 Jan; 9():12. PubMed ID: 18190704
[TBL] [Abstract][Full Text] [Related]
11. Improving the genetic signature of prostate cancer, the somatic mutations.
Martinez-Gonzalez LJ; Pascual Geler M; Robles Fernandez I; Cozar JM; Lorente JA; Alvarez Cubero MJ
Urol Oncol; 2018 Jun; 36(6):312.e17-312.e23. PubMed ID: 29650325
[TBL] [Abstract][Full Text] [Related]
12. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
Yuan J; Kensler KH; Hu Z; Zhang Y; Zhang T; Jiang J; Xu M; Pan Y; Long M; Montone KT; Tanyi JL; Fan Y; Zhang R; Hu X; Rebbeck TR; Zhang L
PLoS Genet; 2020 Feb; 16(2):e1008641. PubMed ID: 32059012
[TBL] [Abstract][Full Text] [Related]
13. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang P; Kitchen-Smith I; Xiong L; Stracquadanio G; Brown K; Richter PH; Wallace MD; Bond E; Sahgal N; Moore S; Nornes S; De Val S; Surakhy M; Sims D; Wang X; Bell DA; Zeron-Medina J; Jiang Y; Ryan AJ; Selfe JL; Shipley J; Kar S; Pharoah PD; Loveday C; Jansen R; Grochola LF; Palles C; Protheroe A; Millar V; Ebner DV; Pagadala M; Blagden SP; Maughan TS; Domingo E; Tomlinson I; Turnbull C; Carter H; Bond GL
Cancer Res; 2021 Apr; 81(7):1667-1680. PubMed ID: 33558336
[TBL] [Abstract][Full Text] [Related]
14. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
[TBL] [Abstract][Full Text] [Related]
15. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
[TBL] [Abstract][Full Text] [Related]
16. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
17. Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants.
LaFramboise WA; Pai RK; Petrosko P; Belsky MA; Dhir A; Howard PG; Becich MJ; Holtzman MP; Ahrendt SA; Pingpank JF; Zeh HJ; Dhir R; Bartlett DL; Choudry HA
Mod Pathol; 2019 Jul; 32(8):1197-1209. PubMed ID: 30962504
[TBL] [Abstract][Full Text] [Related]
18. Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.
Xie CC; Lu L; Sun J; Zheng SL; Isaacs WB; Gronberg H; Xu J
J Hum Genet; 2011 Jul; 56(7):496-502. PubMed ID: 21633361
[TBL] [Abstract][Full Text] [Related]
19. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
20. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
